STOCK TITAN

JanOne Inc - JAN STOCK NEWS

Welcome to our dedicated news page for JanOne (Ticker: JAN), a resource for investors and traders seeking the latest updates and insights on JanOne.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect JanOne's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of JanOne's position in the market.

Rhea-AI Summary
JanOne (JAN) has successfully regained compliance with the minimum bid price requirement of Nasdaq, closing at $1.00 per share or greater for the last 10 consecutive business days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
JanOne (Nasdaq: JAN) to present at Dawson James Securities 8th Annual Investment Conference, highlighting progress in non-addicting painkillers and novel treatments for pain.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
JanOne to discuss innovative approaches to pain management and development of non-addicting treatments for pain at investor sessions
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.19%
Tags
conferences
Rhea-AI Summary
JanOne wins 'Best Abstract' award for reporting effectiveness of Jan101 treatment for diabetic neuropathy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.45%
Tags
none
-
Rhea-AI Summary
JanOne (Nasdaq: JAN) has closed its registered direct offering, raising approximately $790,000 in gross proceeds. The net proceeds will be used for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
offering
-
Rhea-AI Summary
JanOne announces registered direct offering and concurrent private placement of common stock and warrants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
offering
Rhea-AI Summary
JanOne to present data on Jan101's trial in diabetic neuropathy patients at pain management meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.58%
Tags
conferences clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.89%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.48%
Tags
none
JanOne Inc

Nasdaq:JAN

JAN Rankings

JAN Stock Data

13.04M
4.17M
11.46%
9.21%
4.6%
Household Appliance Stores
Retail Trade
Link
US
Las Vegas

About JAN

janone inc. develops treatments for conditions that cause severe pain. the company, through its non-addictive pain-relieving drugs, focuses on reduction for need of opioid prescriptions to treat disease associated pain that can lead to opioid abuse. its lead candidate jan101 provides slow-release formulation of sodium nitrite therapeutic for treatment of peripheral artery disease (pad). the company was formerly known as appliance recycling centers of america, inc. and changed its name to janone inc. in september 2019. janone inc. was founded in 1976 and is headquartered in las vegas, nevada.